Wilshire Pharmaceuticals Inc. is recalling 38,040 bottles of Meclizine HCl tablets (12.5 mg and 25 mg), a prescription medication used to treat vertigo and motion sickness. The recall was initiated because the tablets failed dissolution specifications, meaning they may not dissolve properly in the body to release the active medicine. This defect can lead to the medication being less effective than intended for patients managing their symptoms.
If the tablets do not dissolve correctly, the patient may not receive the full dose of the medication at the expected time, potentially failing to control symptoms of vertigo or motion sickness. No specific injuries or adverse events have been reported in the recall data.
Contact healthcare provider and return to pharmacy.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.